Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul>
<li>The medical technology Company is focussed on the durable healing of wounds and the prevention of amputations through its unique intermittent Topical Wound Oxygen (TWO2) and Negative Pressure Wound (NEXA) therapies, and this morning updated on trading for Y/E December 2024.</li>
<li>Revenue is expected to be more than $58.1m,which is 32% increase on 2023. Growth outside the Veterans Affairs (VA) sector has helped to diversify the sales mix such that the VA sector, whilst continuing to grow, accounted for less than 60% (2023: 72%) of Group revenues.</li>
<li>Investment in new market channels has given earlier access than planned to large and higher margin sectors. </li>
</ul>


The medical technology Company is focussed on the durable healing of wounds and the prevention of amputations through its unique intermittent Topical Wound Oxygen (TWO2) and Negative Pressure Wound (NEXA) therapies, and this morning updated on trading for Y/E December 2024.
Revenue is expected to be more than $58.1m,which is 32% increase on 2023. Growth outside the Veterans Affairs (VA) sector has helped to diversify the sales mix such that the VA sector, whilst continuing to grow, accounted for less than 60% (2023: 72%) of Group revenues.
Investment in new market channels has given earlier access than planned to large and higher margin sectors. 


LPA Group

Hybridan Small Cap Feast: 12/02/2025